Nevro Corp. (NVRO)
USD 3.74
(-7.65%)
USD 3.74
(-7.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 290.06 Million USD | 0.78% |
| 2022 | 276.36 Million USD | 3.88% |
| 2021 | 266.04 Million USD | 6.46% |
| 2020 | 249.9 Million USD | -6.87% |
| 2019 | 268.35 Million USD | -1.82% |
| 2018 | 273.32 Million USD | 20.04% |
| 2017 | 227.69 Million USD | 48.75% |
| 2016 | 153.07 Million USD | 268.97% |
| 2015 | 41.48 Million USD | 94.82% |
| 2014 | 21.29 Million USD | 51.81% |
| 2013 | 14.02 Million USD | 32.04% |
| 2012 | 10.62 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 63.89 Million USD | -0.14% |
| 2024 Q1 | 67.55 Million USD | -13.89% |
| 2023 Q4 | 78.45 Million USD | 12.86% |
| 2023 Q3 | 69.51 Million USD | -6.62% |
| 2023 FY | 278.52 Million USD | 0.78% |
| 2023 Q1 | 64.62 Million USD | -14.11% |
| 2023 Q2 | 74.44 Million USD | 15.19% |
| 2022 Q4 | 75.23 Million USD | 8.57% |
| 2022 Q2 | 72.73 Million USD | 23.09% |
| 2022 Q1 | 59.09 Million USD | -14.52% |
| 2022 FY | 276.36 Million USD | 3.88% |
| 2022 Q3 | 69.3 Million USD | -4.72% |
| 2021 Q2 | 69.98 Million USD | 12.35% |
| 2021 FY | 266.04 Million USD | 6.46% |
| 2021 Q3 | 64.63 Million USD | -7.65% |
| 2021 Q1 | 62.29 Million USD | -20.16% |
| 2021 Q4 | 69.13 Million USD | 6.97% |
| 2020 Q4 | 78.02 Million USD | 2.56% |
| 2020 Q3 | 76.07 Million USD | 115.82% |
| 2020 Q2 | 35.25 Million USD | -41.78% |
| 2020 FY | 249.9 Million USD | -6.87% |
| 2020 Q1 | 60.54 Million USD | -25.49% |
| 2019 Q3 | 69.94 Million USD | 9.38% |
| 2019 Q2 | 63.94 Million USD | 20.17% |
| 2019 Q1 | 53.2 Million USD | -30.13% |
| 2019 FY | 268.35 Million USD | -1.82% |
| 2019 Q4 | 81.25 Million USD | 16.18% |
| 2018 Q2 | 67.92 Million USD | 9.55% |
| 2018 Q3 | 67.24 Million USD | -0.99% |
| 2018 Q4 | 76.15 Million USD | 13.24% |
| 2018 FY | 273.32 Million USD | 20.04% |
| 2018 Q1 | 62 Million USD | -10.81% |
| 2017 Q2 | 53.87 Million USD | 16.19% |
| 2017 FY | 227.69 Million USD | 48.75% |
| 2017 Q4 | 69.51 Million USD | 19.97% |
| 2017 Q3 | 57.94 Million USD | 7.55% |
| 2017 Q1 | 46.36 Million USD | -5.06% |
| 2016 Q1 | 25.98 Million USD | 27.68% |
| 2016 Q2 | 36.55 Million USD | 40.68% |
| 2016 Q3 | 41.68 Million USD | 14.03% |
| 2016 FY | 153.07 Million USD | 268.97% |
| 2016 Q4 | 48.83 Million USD | 17.16% |
| 2015 Q4 | 20.35 Million USD | 115.74% |
| 2015 Q3 | 9.43 Million USD | 59.63% |
| 2015 Q2 | 5.91 Million USD | 2.09% |
| 2015 Q1 | 5.78 Million USD | -13.53% |
| 2015 FY | 41.48 Million USD | 94.82% |
| 2014 Q1 | 3.66 Million USD | 0.58% |
| 2014 FY | 21.29 Million USD | 51.81% |
| 2014 Q4 | 6.69 Million USD | 12.88% |
| 2014 Q3 | 5.93 Million USD | 18.53% |
| 2014 Q2 | 5 Million USD | 36.53% |
| 2013 Q3 | 3.72 Million USD | 10.23% |
| 2013 FY | 14.02 Million USD | 32.04% |
| 2013 Q4 | 3.64 Million USD | -2.25% |
| 2013 Q1 | 3.27 Million USD | 0.0% |
| 2013 Q2 | 3.38 Million USD | 3.33% |
| 2012 FY | 10.62 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott Laboratories | 22.13 Billion USD | 98.69% |
| Allurion Technologies Inc. | 41.49 Million USD | -598.99% |
| Artivion, Inc. | 229.17 Million USD | -26.566% |
| Avanos Medical, Inc. | 379.7 Million USD | 23.608% |
| Butterfly Network, Inc. | 16.85 Million USD | -1620.812% |
| Butterfly Network, Inc. | 16.85 Million USD | -1620.812% |
| Bio-Rad Laboratories, Inc. | 1.43 Billion USD | 79.735% |
| Boston Scientific Corporation | 9.89 Billion USD | 97.069% |
| Perspective Therapeutics, Inc. | 1.63 Million USD | -17651.53% |
| CONMED Corporation | 643.06 Million USD | 54.894% |
| Edwards Lifesciences Corporation | 4.62 Billion USD | 93.728% |
| Paragon 28, Inc. | 172.79 Million USD | -67.868% |
| Glaukos Corporation | 239.13 Million USD | -21.295% |
| Globus Medical, Inc. | 1.02 Billion USD | 71.571% |
| Inspire Medical Systems, Inc. | 528.22 Million USD | 45.088% |
| Integer Holdings Corporation | 418.28 Million USD | 30.656% |
| Medtronic plc | 19.45 Billion USD | 98.509% |
| Owlet, Inc. | 22.58 Million USD | -1184.19% |
| Penumbra, Inc. | 682.64 Million USD | 57.509% |
| Vicarious Surgical Inc. | -1.85 Million USD | 15745.092% |
| Smith & Nephew plc | 3.7 Billion USD | 92.163% |
| Sonendo, Inc. | 10.72 Million USD | -2605.279% |
| STERIS plc | 2.23 Billion USD | 87.016% |
| Stryker Corporation | 13.05 Billion USD | 97.779% |
| Vapotherm, Inc. | 28.28 Million USD | -925.563% |
| Zimmer Biomet Holdings, Inc. | 5.31 Billion USD | 94.538% |